8dv5: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
-The entry 8dv5 is ON HOLD
+==Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6'-hydroxy-1'-(4-((1-pentylpyrrolidin-3-yl)methoxy)phenyl)-1',4'-dihydro-2'<i>H</i>-spiro[cyclopropane-1,3'-isoquinolin]-2'-yl)(phenyl)methanone==
+<StructureSection load='8dv5' size='340' side='right'caption='[[8dv5]], [[Resolution|resolution]] 1.85&Aring;' scene=''>
+== Structural highlights ==
+<table><tr><td colspan='2'>[[8dv5]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8DV5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8DV5 FirstGlance]. <br>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.85&#8491;</td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=TX9:[(1R)-6-hydroxy-1-(4-{[(3S)-1-pentylpyrrolidin-3-yl]methoxy}phenyl)-1,4-dihydro-2H-spiro[cyclopropane-1,3-isoquinolin]-2-yl](phenyl)methanone'>TX9</scene></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8dv5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8dv5 OCA], [https://pdbe.org/8dv5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8dv5 RCSB], [https://www.ebi.ac.uk/pdbsum/8dv5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8dv5 ProSAT]</span></td></tr>
+</table>
+== Function ==
+[https://www.uniprot.org/uniprot/ESR1_HUMAN ESR1_HUMAN] Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.<ref>PMID:7651415</ref> <ref>PMID:10970861</ref> <ref>PMID:9328340</ref> <ref>PMID:10681512</ref> <ref>PMID:10816575</ref> <ref>PMID:11477071</ref> <ref>PMID:11682626</ref> <ref>PMID:15078875</ref> <ref>PMID:16043358</ref> <ref>PMID:15891768</ref> <ref>PMID:16684779</ref> <ref>PMID:18247370</ref> <ref>PMID:17932106</ref> <ref>PMID:19350539</ref> <ref>PMID:20705611</ref> <ref>PMID:21937726</ref> <ref>PMID:21330404</ref> <ref>PMID:22083956</ref>
-Authors: Hancock, G.R., Young, K.S., Hosfield, D.J., Joiner, C., Sullivan, E.A., Yildz, Y., Laine, M., Greene, G.L., Fanning, S.W.
+==See Also==
+*[[Estrogen receptor 3D structures|Estrogen receptor 3D structures]]
-Description: Estrogen Receptor Alpha Ligand Binding Domain in Complex with (6''-hydroxy-1''-(4-((1-pentylpyrrolidin-3-yl)methoxy)phenyl)-1'',4''-dihydro-2''<i>H</i>-spiro[cyclopropane-1,3''-isoquinolin]-2''-yl)(phenyl)methanone
+== References ==
-[[Category: Unreleased Structures]]
+<references/>
-[[Category: Laine, M]]
+__TOC__
-[[Category: Sullivan, E.A]]
+</StructureSection>
-[[Category: Young, K.S]]
+[[Category: Homo sapiens]]
-[[Category: Joiner, C]]
+[[Category: Large Structures]]
-[[Category: Hosfield, D.J]]
+[[Category: Fanning SW]]
-[[Category: Hancock, G.R]]
+[[Category: Greene GL]]
-[[Category: Greene, G.L]]
+[[Category: Hancock GR]]
-[[Category: Fanning, S.W]]
+[[Category: Hosfield DJ]]
-[[Category: Yildz, Y]]
+[[Category: Joiner C]]
+[[Category: Laine M]]
+[[Category: Sullivan EA]]
+[[Category: Yildz Y]]
+[[Category: Young KS]]